Over RMB 300 Million AI-Cell Therapy Partnership Sealed as Inbrex Bio and Deep Intelligent Pharma File IPO Prospectus

Hangzhou, China, January 26, 2026,Deep Intelligent Pharma (DIP), a global leading AI-driven drug discovery platform, announced today that it has officially signed a comprehensive strategic cooperation agreement with Inbrex Bio, a leader in universal cell therapy.

This signing coincides with the unveiling of ImmBio's "Zhejiang Provincial Enterprise Research Institute" and the official launch of its new Medical Research Center. According to the agreement, both parties jointly launched the ACC-NK Cell Therapy AI Intelligent Platform, reaching an in-depth cooperation intention worth over 300 million RMB. Deep Intelligent Pharma will act as ImmBio’s comprehensive strategic partner, providing robust AI computing power and algorithm support to ImmBio’s newly established Medical Research Center through its core Deep AI Scientist platform, accelerating the global commercialization process of universal NK cell therapy (ACC-NK).

The signing of this billion-dollar strategic contract marks the substantial implementation of the "AI+Biotech" model on top-tier R&D platforms.

On January 26, ImmunoBrain Therapeutics held a grand "Unveiling Ceremony of Zhejiang Provincial Enterprise Research Institute" at its headquarters in Hangzhou and was awarded the "Quasi-Unicorn" honor by the government. As one of the first core technology partners of this high-level R&D platform, Deep Intelligent Pharma will be deeply involved in ImmunoBrain Therapeutics' R&D pipeline. The signing of this hundred-million-yuan strategic contract not only reflects ImmunoBrain Therapeutics' high recognition of Deep Intelligent Pharma's AI technical strength but also marks the transformation of Deep Intelligent Pharma's commercialization model from single technical service to "deep binding with strategic large customers."

Currently, Deep Intelligent Pharma and ImmunoBrain Therapeutics are both at a critical stage of rapid development. ImmunoBrain Therapeutics has become a star company in the field of cell therapy with its globally pioneering IBR854 for solid tumors and IBR733 for AML. Deep Intelligent Pharma, on the other hand, has reshaped the efficiency logic of drug development through its unique approach of "AI defining clinical."

This collaboration will focus on addressing the challenges of solid tumor treatment and the scalable production of cell therapies, among other industry pain points. The strong partnership between the two parties will also jointly enhance their brand influence in the international market.

This collaboration has also drawn significant attention in the capital markets. Several industry analysts believe that this "AI platform + innovative drug pipeline" deep integration could become the standard configuration for future innovative drug CRO companies. A well-known biopharmaceutical industry analyst and the head of pharmaceuticals at a leading securities firm commented: "In the Hong Kong Stock Exchange's Chapter 18A sector, a single technological narrative is no longer enough to impress investors. The combination of ImmunoBrite and Deep Intelligent Pharma leverages each party’s strengths. For ImmunoBrite, the integration of AI implies more controllable R&D timelines and lower CMC costs, which directly impacts post-IPO profit margins. For Deep Intelligent Pharma, having a heavyweight clinical-stage pipeline like ImmunoBrite as a validation scenario demonstrates that its AI technology is not just 'icing on the cake' but rather 'a lifeline in a snowstorm.' This '1+1>2' ecosystem synergy holds great promise for achieving valuation premiums in the secondary market."

Another senior partner of a medical-focused fund who has long been following both companies said, "We are very optimistic about this 'resource exchange' cooperation model. Especially in the field of cell therapy, AI empowerment may be the inevitable path for the future. If both parties can successfully bring IBR854 to market, this will become a textbook case of 'AI-defined drugs' on a global scale."

Hangzhou Yingbai Rui Biopharmaceutical Co., Ltd. is an innovative biopharmaceutical company dedicated to addressing unmet clinical needs. Currently, Yingbai Rui has established four core products that lead the industry, including off-the-shelf universal full-cycle product lines, autoimmune disease management product lines, comprehensive cancer treatment solutions, and ADC+NK combination therapy regimens. The company has built a portfolio of 16 product pipelines covering multiple fields such as oncology, autoimmune diseases, and neurological disorders, initiating a new paradigm in NK cell therapy. Several products have entered Phase II clinical trials, demonstrating significant clinical application value and are expected to become the world's fastest-to-market innovative NK cell immunotherapy drugs.

Deep Intelligent Pharma (DIP) is a globally leading AI-driven drug discovery and commercialization platform dedicated to reshaping the entire drug development process through artificial intelligence technology. The company’s core product, Deep AI Scientist (a comprehensive AI scientific system), integrates big data, large language models (LLM), and multimodal biocomputing technologies, offering full-chain capabilities ranging from target discovery, molecule generation, CMC optimization, to automatic generation and simulation of clinical trials. DIP has served thousands of pharmaceutical companies and biotech firms worldwide. As an advocate of “AI-defined clinical,” Deep Intelligent Pharma is leveraging technology to significantly shorten the time-to-market for new drugs, reduce R&D costs, and benefit patients globally.